General Meeting Result....all resolutions passed22 May 2020 13:23
Fri, 22nd May 2020 12:04
RNS Number : 7842N
ValiRx PLC
22 May 2020
VALIRX PLC
("ValiRx", the "Company" or the "Group")
Result of General Meeting and Total Voting Rights
London, UK., 22 May 2020: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company announces that, at the General Meeting of the Company held earlier today, all resolutions were duly passed.
The poll results are set out below:-
Resolutions
For
Against
Discretion
Resolution 1 (Ordinary)
Allotment of share capital
1,994,665
39,045
2,031
Resolution 2 (Special)
Dis-application of pre-emptive rights
1,968,954
66,423
2,040
As a consequence, further to the announcements of 4 May 2020 and of 6 May 2020, application has been made for the 18,069,467 new ordinary shares to be admitted to trading on AIM, which is expected to occur on or around 26 May 2020. There are no shares held in treasury. The 18,069,467 new ordinary shares will rank pari passu with the existing ordinary shares of ValiRx.
Following admission, the Company will have in issue 36,062,373 ordinary shares with voting rights. The above figure may be used by shareholders as the denominator for calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Disclosure and Transparency rules.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For more information, please contact:
ValiRx plc
Tel: +44 (0) 20 7073 2628
www.valirx.com
Kevin Alexander
Cairn Financial Advisers LLP (Nominated Adviser)
Liam Murray / Jo Turner / Ludovico Lazzaretti
Tel: +44 (0) 20 7213 0880
Peterhouse Capital Limited (Sole Broker)
Duncan Vasey / Lucy Williams / Eran Zucker
Tel: +44 (0) 20 7469 0930